Valeur202020212022202320242025TTMFlux de trésorerie liés aux activités d'investissement78.35 M-406.29 M-487 M-96.91 M-262.72 M-545.81 M-458.27 MFlux de trésorerie liés aux activités de financement-106.28 M77.86 M362.37 M-407.99 M-218.86 M-85.17 M-83.47 MFlux de trésorerie disponible55.45 M299.44 M240.11 M388.57 M479.06 M644.59 M667.65 M
Halozyme Therapeutics, Inc. - Common Stock
Halozyme Therapeutics, Inc. is an American biotechnology company. It develops oncology therapies designed to target the tumor microenvironment.
The company was founded in 1998 and went public in 2004. Halozyme is headquartered in San Diego, California.